CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

British Journal of Clinical Pharmacology
Han-Jing CenLi-Zi Zhao

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Genetic polymorphisms of VKORC1 and CYP2C9 are known to influence warfarin dosage. * Recent studies among Caucasians showed that polymorphisms of CYP4F2 also play a role in warfarin pharmacogenetics. * The contribution of CYP4F2 variants to the variability inwarfarin dose requirement in Chinese subjects remains to be investigated. WHAT THIS STUDY ADDS * This research was to study the effect of CYP4F2 variants on warfarin requirements in the Han Chinese population. * This study developed a multiple regression model including CYP2C9, VKORC1 3673G>A, CYP4F2 genotypes and age, weight, combination use of amiodarone which could explain 56.1% of the individual variability in warfarin dose CYP4F2 could explain 4% of the variance in warfarin dose. * We found that one novel genotypic polymorphism 5417G>T for Asp36Tyr, which was identified as an important marker of warfarin resistance, was absent in the Han Chinese population in our study. AIMS The objective of this study was to assess the effect of the CYP4F2 on the daily stable warfarin dose requirement in Han Chinese patients with mechanical heart valve replacement (MHVR). METHODS From March 2007 to November 2008, 222 Han Chinese MHVR patients...Continue Reading

References

Sep 1, 1976·Nucleic Acids Research·N Blin, D W Stafford
Aug 1, 1996·Pharmacogenetics·T H Sullivan-KloseJ A Goldstein
Jan 28, 1999·Biochemical and Biophysical Research Communications·U YasarF Sjöqvist
May 9, 2002·The Journal of Biological Chemistry·Timothy J Sontag, Robert S Parker
Dec 20, 2003·Nature·UNKNOWN International HapMap Consortium
Dec 24, 2003·Thrombosis and Haemostasis·Brian F GageHoward L McLeod
Jul 31, 2004·Pharmacogenetics·Michael A HillmanJames K Burmester
May 25, 2005·Archives of Internal Medicine·Anne M HolbrookPhilip S Wells
Sep 15, 2005·Clinical Medicine & Research·Michael A HillmanJames K Burmester
May 17, 2006·Basic & Clinical Pharmacology & Toxicology·Claire Larramendy-GozaloLaurent Becquemont
May 19, 2006·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Viroj Wiwanitkit
Aug 8, 2006·Clinical Pharmacology and Therapeutics·Kyoko ObayashiRyuya Horiuchi
Apr 26, 2007·Clinical Medicine & Research·Michael D CaldwellJames K Burmester
Feb 6, 2008·Blood·Michael D CaldwellJames K Burmester
Aug 6, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Ting-Liang WangSusan Tai
Aug 30, 2008·Clinical Pharmacology and Therapeutics·J A PeriniG Suarez-Kurtz

❮ Previous
Next ❯

Citations

Mar 2, 2011·The Pharmacogenomics Journal·A PavaniV K Kutala
Aug 15, 2013·Genetic Testing and Molecular Biomarkers·Yundan LiangBingying Xu
Apr 11, 2013·Thrombosis and Haemostasis·Mohamed Hossam A ShahinJulie A Johnson
Jun 10, 2014·Pharmacological Reports : PR·Risha NaharIshwar C Verma
Dec 17, 2011·Journal of Clinical Pharmacy and Therapeutics·K NakamuraK Yamamoto
Oct 26, 2011·British Journal of Clinical Pharmacology·May P S Lam, Bernard M Y Cheung
May 18, 2012·British Journal of Clinical Pharmacology·Rashmi R Shah, Devron R Shah
Dec 15, 2010·British Journal of Clinical Pharmacology·Yoon K LokeJames M Ritter
Jul 16, 2015·Environmental Toxicology and Pharmacology·Csilla SipekyBela Melegh
Nov 19, 2010·Drug Metabolism and Pharmacokinetics·Onkar SinghBalram Chowbay
Sep 29, 2012·The EPMA Journal·Liliya Alexandrovna BelozercevaValentin Viktorovich Vlasov
Sep 22, 2016·Advances in Medicine·Ruta SakieneRasa Liutkeviciene
Nov 6, 2014·Pharmacogenetics and Genomics·Maria L AlvarellosTeri E Klein
Apr 28, 2018·Pharmacogenomics·Letícia C TavaresPaulo C J L Santos
Feb 27, 2018·European Journal of Clinical Pharmacology·Marwa AjmiAli Bouslama
Apr 14, 2019·Journal of Clinical Pharmacy and Therapeutics·Palden Wangyel DorjiKesara Na-Bangchang
Sep 12, 2015·Journal of Cardiovascular Pharmacology·Sameh Alzubiedi, Mohammad I Saleh
May 28, 2017·European Journal of Clinical Pharmacology·Nitsupa WattanachaiWichittra Tassaneeyakul
Jun 8, 2018·Frontiers in Pharmacology·Letícia C TavaresPaulo C J L Santos
Jul 28, 2018·European Journal of Clinical Pharmacology·Letícia C TavaresPaulo Caleb Junior Lima Santos
Dec 13, 2016·BMC Research Notes·William KudziRichard Harry Asmah
Feb 13, 2019·The Pharmacogenomics Journal·Xi LiJi-Ye Yin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.